Nektar Therapeutics Investing Cash Flow
Nektar Therapeutics (NKTR) reported Investing Cash Flow of -$749.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-14
- Nektar Therapeutics net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$399.11M, a 904.41% decline year-over-year.
- Nektar Therapeutics net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$350.79M, a 902.92% decline year-over-year.
- Nektar Therapeutics net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $372.00K, a 99.38% decline year-over-year.
- Nektar Therapeutics net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$94.87M, a 305.73% decline year-over-year.
- Nektar Therapeutics net cash provided by (used in) investing activities for fiscal 2025 was -$1.20M, a 100.84% decline from fiscal 2024.
- Nektar Therapeutics net cash provided by (used in) investing activities for fiscal 2024 was $142.57M, a 2.15% increase from fiscal 2023.
- Nektar Therapeutics net cash provided by (used in) investing activities for fiscal 2023 was $139.56M, a 61.85% decline from fiscal 2022.
- Nektar Therapeutics net cash provided by (used in) investing activities for fiscal 2022 was $365.83M, a 80.41% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$399.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$749.90M 10-Q · filed 2026-08-14 | -$749.53M derived: sum of 3 quarters · filed 2026-08-14 | -$844.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$350.79M 10-Q · filed 2026-05-08 | -$350.42M derived: sum of 2 quarters · filed 2026-05-08 | -$445.29M derived: sum of 3 quarters · filed 2026-05-08 | -$395.68M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$94.50M derived: sum of 2 quarters · filed 2026-03-13 | -$44.89M derived: sum of 3 quarters · filed 2026-08-14 | -$1.20M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$94.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$45.26M derived: sum of 2 quarters · filed 2026-08-14 | -$1.57M 10-Q · filed 2025-11-07 | $58.65M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $49.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $93.30M 10-Q · filed 2026-08-14 | $153.52M derived: sum of 3 quarters · filed 2026-08-14 | $199.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $43.69M 10-Q · filed 2026-05-08 | $103.90M derived: sum of 2 quarters · filed 2026-05-08 | $150.02M derived: sum of 3 quarters · filed 2026-05-08 | $167.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $60.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $106.33M derived: sum of 2 quarters · filed 2026-03-13 | $123.31M derived: sum of 3 quarters · filed 2026-03-13 | $142.57M 10-K · filed 2026-03-13 |
| 2024-09-30 | $46.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $63.10M derived: sum of 2 quarters · filed 2025-11-07 | $82.36M 10-Q · filed 2025-11-07 | $99.74M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $16.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $36.24M 10-Q · filed 2025-08-08 | $53.62M derived: sum of 3 quarters · filed 2025-08-08 | $110.03M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $19.26M 10-Q · filed 2025-05-09 | $36.64M derived: sum of 2 quarters · filed 2025-05-09 | $93.05M derived: sum of 3 quarters · filed 2025-05-09 | $118.22M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $17.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $73.80M derived: sum of 2 quarters · filed 2025-03-14 | $98.97M derived: sum of 3 quarters · filed 2025-03-14 | $139.56M 10-K · filed 2025-03-14 |
| 2023-09-30 | $56.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $81.58M derived: sum of 2 quarters · filed 2024-11-08 | $122.18M 10-Q · filed 2024-11-08 | $162.19M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $25.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $65.77M 10-Q · filed 2024-08-09 | $105.78M derived: sum of 3 quarters · filed 2024-08-09 | $217.18M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $40.60M 10-Q · filed 2024-05-10 | $80.61M derived: sum of 2 quarters · filed 2024-05-10 | $192.01M derived: sum of 3 quarters · filed 2024-05-10 | $276.15M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $40.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $151.41M derived: sum of 2 quarters · filed 2024-03-05 | $235.56M derived: sum of 3 quarters · filed 2024-03-05 | $365.83M 10-K · filed 2024-03-05 |
| 2022-09-30 | $111.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $195.54M derived: sum of 2 quarters · filed 2023-11-08 | $325.82M 10-Q · filed 2023-11-08 | $446.02M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $84.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $214.43M 10-Q · filed 2023-08-09 | $334.62M derived: sum of 3 quarters · filed 2024-03-05 | $333.79M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $130.28M 10-Q · filed 2023-05-10 | $250.47M derived: sum of 2 quarters · filed 2024-03-05 | $249.65M derived: sum of 3 quarters · filed 2024-03-05 | $322.60M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $120.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $119.37M derived: sum of 2 quarters · filed 2024-03-05 | $192.32M derived: sum of 3 quarters · filed 2024-03-05 | $202.78M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$830.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $72.12M derived: sum of 2 quarters · filed 2022-11-04 | $82.58M 10-Q · filed 2022-11-04 | $175.32M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $72.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $83.41M 10-Q · filed 2022-08-05 | $176.15M derived: sum of 3 quarters · filed 2023-02-28 | $224.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $10.46M 10-Q · filed 2022-05-06 | $103.20M derived: sum of 2 quarters · filed 2023-02-28 | $151.87M derived: sum of 3 quarters · filed 2023-02-28 | $308.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $92.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $141.41M derived: sum of 2 quarters · filed 2023-02-28 | $298.45M derived: sum of 3 quarters · filed 2023-02-28 | $496.21M 10-K · filed 2023-02-28 |
| 2020-09-30 | $48.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $205.71M derived: sum of 2 quarters · filed 2021-11-05 | $403.47M 10-Q · filed 2021-11-05 | $538.95M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $157.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $354.81M 10-Q · filed 2021-08-06 | $490.29M derived: sum of 3 quarters · filed 2022-03-01 | $548.54M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $197.77M 10-Q · filed 2021-05-07 | $333.25M derived: sum of 2 quarters · filed 2022-03-01 | $391.50M derived: sum of 3 quarters · filed 2022-03-01 | $416.79M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $135.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $193.73M derived: sum of 2 quarters · filed 2022-03-01 | $219.02M derived: sum of 3 quarters · filed 2022-03-01 | $206.89M 10-K · filed 2022-03-01 |
| 2019-09-30 | $58.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $83.54M derived: sum of 2 quarters · filed 2020-11-06 | $71.41M 10-Q · filed 2020-11-06 | $158.94M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $25.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $13.15M 10-Q · filed 2020-08-07 | $100.69M derived: sum of 3 quarters · filed 2021-02-26 | -$520.58M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$12.14M 10-Q · filed 2020-05-08 | $75.40M derived: sum of 2 quarters · filed 2021-02-26 | -$545.87M derived: sum of 3 quarters · filed 2021-02-26 | -$1.44B derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $87.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$533.73M derived: sum of 2 quarters · filed 2021-02-26 | -$1.43B derived: sum of 3 quarters · filed 2021-02-26 | -$1.38B 10-K · filed 2021-02-26 |
| 2018-09-30 | -$621.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$1.52B derived: sum of 2 quarters · filed 2019-11-07 | -$1.47B 10-Q · filed 2019-11-07 | -$1.44B derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | -$894.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$846.21M 10-Q · filed 2019-08-09 | -$823.23M derived: sum of 3 quarters · filed 2020-02-28 | -$903.92M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $48.21M 10-Q · filed 2019-05-09 | $71.19M derived: sum of 2 quarters · filed 2020-02-28 | -$9.50M derived: sum of 3 quarters · filed 2020-02-28 | |
| 2017-12-31 | $22.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$57.71M derived: sum of 2 quarters · filed 2020-02-28 | -$28.81M 10-K · filed 2020-02-28 | |
| 2017-09-30 | -$80.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$51.79M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $28.90M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$82.40M 10-K · filed 2019-03-01 | |||
| 2013-12-31 | -$82.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$40.37M derived: sum of 2 quarters · filed 2014-02-27 | $6.22M derived: sum of 3 quarters · filed 2014-02-27 | $49.91M 10-K · filed 2014-02-27 |
| 2013-09-30 | $41.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $88.37M derived: sum of 2 quarters · filed 2013-11-07 | $132.06M 10-Q · filed 2013-11-07 | $194.29M derived: sum of 4 quarters · filed 2014-02-27 |
| 2013-06-30 | $46.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $90.28M 10-Q · filed 2013-08-09 | $152.51M derived: sum of 3 quarters · filed 2014-02-27 | $147.12M derived: sum of 4 quarters · filed 2014-02-27 |
| 2013-03-31 | $43.69M 10-Q · filed 2013-05-09 | $105.91M derived: sum of 2 quarters · filed 2014-02-27 | $100.52M derived: sum of 3 quarters · filed 2014-02-27 | $108.28M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-12-31 | $62.23M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $56.84M derived: sum of 2 quarters · filed 2014-02-27 | $64.59M derived: sum of 3 quarters · filed 2014-02-27 | $113.02M 10-K · filed 2014-02-27 |
| 2012-09-30 | -$5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $2.37M derived: sum of 2 quarters · filed 2013-11-07 | $50.79M 10-Q · filed 2013-11-07 | $65.19M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $7.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $56.18M 10-Q · filed 2013-08-09 | $70.58M derived: sum of 3 quarters · filed 2014-02-27 | $123.32M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $48.42M 10-Q · filed 2013-05-09 | $62.83M derived: sum of 2 quarters · filed 2014-02-27 | $115.56M derived: sum of 3 quarters · filed 2014-02-27 | $138.36M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $67.13M derived: sum of 2 quarters · filed 2014-02-27 | $89.93M derived: sum of 3 quarters · filed 2014-02-27 | -$111.95M 10-K · filed 2014-02-27 |
| 2011-09-30 | $52.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $75.53M derived: sum of 2 quarters · filed 2012-11-09 | -$126.35M 10-Q · filed 2012-11-09 | -$143.52M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $22.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$179.09M 10-Q · filed 2012-08-09 | -$196.25M derived: sum of 3 quarters · filed 2013-03-01 | -$184.75M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$201.88M 10-Q · filed 2012-05-04 | -$219.05M derived: sum of 2 quarters · filed 2013-03-01 | -$207.55M derived: sum of 3 quarters · filed 2013-03-01 | -$186.19M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | -$17.16M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$5.67M derived: sum of 2 quarters · filed 2013-03-01 | $15.69M derived: sum of 3 quarters · filed 2013-03-01 | $16.71M 10-K · filed 2013-03-01 |
| 2010-09-30 | $11.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $32.85M derived: sum of 2 quarters · filed 2011-11-04 | $33.88M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $21.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $22.38M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $1.02M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | -$149.03M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |